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Background:  Arterial pulse pressure (PP) is considered as an independent cardiovascular risk 
factor. We compared PP during an active orthostatic test in middle-aged patients with type 1 
diabetes and with type 2 diabetes, and corresponding nondiabetic controls. 
 
Methods: 40 patients with type 1 diabetes (mean age 50 years, diabetes duration 23 years, BMI 
23.0 kg/m²) were compared to 40 non hypertensive patients with type 2 diabetes (respectively, 
50 years, 8 years, 29.7 kg/m²). Patients taking antihypertensive agents or with renal insufficiency 
were excluded. All patients were evaluated with a continuous noninvasive arterial blood pressure 
monitoring (Finapres®) in standing (1 min), squatting (1 min) and again standing position (1 
min). Patients with type 1 or type 2 diabetes were compared with two groups of 40 age-, sex- and 
BMI-matched healthy subjects.  
 
Results: Patients with type 1 diabetes and patients with type 2 diabetes showed significantly 
higher PP, heart rate (HR) and PPxHR double product (type 1 : 5263 vs 4121 mmHg/min, 
p=0.0004; type 2 : 5359 vs 4321 mmHg, p=0.0023) levels than corresponding controls. There 
were no significant differences between patients with type 1 diabetes and type 2 diabetes 
regarding PP (59 vs 58 mmHg), HR (89 vs 88/min), and PPxHR product (5263 vs 5359 
mmHg/min).  
  
Conclusion: Patients with type 1 diabetes have comparable increased levels of peripheral PP, an 
indirect marker of arterial stiffness, and PPxHR, an index of pulsatile stress, as non-hypertensive 




rterial pulse pressure (PP), a 
surrogate marker of large 
artery stiffness, was shown to 
be an independent cardiovascular disease 
(CVD) risk factor in several large longitudinal 
studies in patients with type 2 diabetes 
mellitus (1,2). In patients with type 1 diabetes 
of the Finnish Diabetic Nephropathy 
(FinnDiane) study (3), a higher systolic blood 
pressure (BP) and an earlier decrease in 
diastolic BP resulted in a higher and more 
rapidly increasing PP as compared to non-
diabetic control subjects. In the EURODIAB 
study (4,5), PP was also an independent risk 
factor for CVD and total mortality in patients 
with type 1 patients.  
Middle-aged patients with type 1 
diabetes are characterized by a long duration 
of the disease and therefore a sustained 
exposure to chronic hyperglycaemia, leading 
to accelerated progression of arterial stiffness 
and increased PP (6). In contrast, middle-aged 
patients with type 2 diabetes have a much 
shorter duration of diabetes, but have other 
CVD risk factors such as abdominal obesity, 
insulin resistance and metabolic syndrome, 
which could accelerate arterial stiffness (1,2). 
To our knowledge, no study compared PP in 
patients with type 1 diabetes and in patients 
with type 2 diabetes at similar age. The 
primary aim of the present study was to 
investigate pulsatile stress in patients with 
type 1 and patients with type 2 diabetes at a 
similar mean age of 50 years. Each group of 
diabetic patients was compared with a group 
of nondiabetic controls, matched for age, sex, 
and body mass index (BMI). BP and PP were 
monitored during an active postural test, the 
so-called squatting test, which has been 
shown by our group to amplify PP increase 
A
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according to diabetes duration in patients with 
type 1 diabetes (7,8). 
 
RESEARCH DESIGN AND METHODS  
Patients. Forty patients (20 men and 20 
women) with type 1 diabetes and 40 patients 
(20 men and 20 women) with type 2 diabetes 
were recruited among the patients followed in 
our department. Patients with arterial 
hypertension, renal insufficiency or CVD or 
taking medications interfering with vascular 
reactivity (including any type of 
antihypertensive agents) were excluded from 
the study. All patients with type 1 diabetes 
received intensified insulin therapy with 
multiple daily insulin injections (n = 36) or 
continuous subcutaneous insulin infusion via 
a portable pump (n = 4). Patients with type 2 
diabetes received various types of oral 
glucose-lowering therapies (metformin alone, 
sulfonylurera alone or metformin-
sulfonylurea combination) (n = 25) or insulin 
alone (n = 5) or combined with metformin (n 
= 10). Two groups of healthy subjects were 
used as controls and matched for BMI with 
either type 1 diabetes patients or type 2 
diabetes patients (Table 1). The study was 
accepted by the ethical committee of our 
institution.  
Orthostatic test. The squatting test 
(successively 1 min standing, 1 min squatting, 
1 min standing) is an original active 
orthostatic manoeuvre that leads to the most 
important and fast variations of the 
hydrostatic level with posture (9). Squatting 
produces a prompt increase in cardiac output 
and arterial BP, essentially attributed to 
augmented venous return from compression 
of leg veins. These changes result in a 
significant increase in mean arterial BP and 
PP (7,8), which is accompanied by an 
immediate decrease in heart rate (HR) and 
forearm vascular resistance, probably due to 
activation of cardiopulmonary and arterial 
baroreflexes implicating autonomic nervous 
system. Later on, the active transition from 
squatting to standing results in a profound 
initial BP decrease inducing a reflex 
tachycardia, which can be used to detect 
diabetic cardiac autonomic neuropathy (CAN) 
(10,11) and assess baroreflex sensitivity (12).  
Measurements. Changes in systolic BP 
(SBP), diastolic BP and HR were measured 
continuously with a FinapresR (from FINger 
Arterial PRESsure) instrument (Ohmeda, 
USA) that allows to carefully study 
cardiovascular reflexes, especially during an 
orthostatic manoeuvre (13). The FinapresR is 
based on servoplethysmomanometry, 
employing the volume clamp technique at the 
finger level. A good concordance was 
reported between Finapres® BP 
measurements and direct intra-arterial 
measurements (13).  PP, i.e. SBP minus 
diastolic BP, was automatically calculated 
throughout the test. Mean arterial blood 
pressure (MBP) was calculated by the 
formula (SBP + 2 x diastolic BP)/3. To 
quantify the relative magnitude of the 
pulsatile to mean artery pressure (“pulsatility 
index”), we normalised the PP to the MBP 
and referred to this value as fractional PP 
(PPf) (14). “Pulsatile stress” was defined as 
the double product of PP and HR; it has been 
shown to be largely regulated by arterial 
stiffness and by sympathetic nerve activity 
and to be associated with a higher risk of 
(micro)albminuria (15). We also calculated 
the “SBP x HR” double product, an index of 
cardiac load that has been shown to be 
associated with an increased CVD risk (16). 
For each variable or parameter, mean levels 
were calculated in each subject during the 
whole period of the test, during the initial 
standing position and during the squatting 
position, after exclusion of the initial 
transition phase, as previously described 
(7,8). 
During the transition from squatting to 
standing, there is an abrupt drop in BP 
associated with a reflex tachycardia, and that 
is followed by a rapid return to baseline 
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values of both parameters (BP increase and 
HR decrease). The mirror changes in HR and 
SBP allows the calculation of a baroreflex 
gain, by plotting the pulse intervals (R-R) 
against SBP values, and the slope of this 
relation represents the baroreflex sensitivity 
(17). We also calculated both a vagal index 
(SqTv : ratio between the baseline cardiac R-
R interval and the longest R-R interval in the 
first 15 sec of squatting) and a sympathetic 
index (SqTs : ratio between the baseline 
cardiac R-R interval and the shortest R-R 
interval in the first 10–20 seconds of standing 
after squatting), as previously described 
(10,11). These indices, based on HR reduction 
during squatting and reflex tachycardia during 
standing, were considered as markers of 
cardiovascular autonomic neuropathy (CAN) 
: a higher SqtV value indicates a 
parasympathetic neuropathy while a lower 
SqTs is an indicator of sympathetic 
neuropathy (10-12). 
Concomitant glycated hemoglobin 
(HbA1c) levels (normal values 4-6 %) were 
measured in order to assess recent blood 
glucose control in diabetic patients; for each 
patient, corresponding HbA1c mean level 
corresponded to the average of 1 to 3 
measurements. Lipid profiles were also 
collected in diabetic patients and the 
prevalence of the metabolic syndrome 
(National Cholesterol Education Program – 
Adult Treatment Panel 3 criteria) was 
calculated in patients with type 1 diabetes and 
in patients with type 2 diabetes.     
Statistical analysis. The required sample size 
to have an 80% chance of detecting as 
significant (at the two sided 5% level) a 10 
mm Hg difference in PP between two 
different subgroups, with an assumed 
standard deviation of PP of 14 mmHg, was 32 
individuals. A difference of 10 mm Hg was 
chosen as clinically significant because it has 
been shown to be associated with increased 
cardiovascular mortality in type 2 diabetes (1) 
and total mortality in the large EURODIAB 
cohort of patients with type 1 diabetes (5). 
Between-group differences were analyzed 
using unpaired t tests. The relationship 
between two variables, i.e. between pulsatile 
stress and baroreflex gain as a marker of 
CAN, was assessed with the Spearman 
correlation coefficient. Results were 
expressed as mean ± SD values for all 
continuous variables. A p value of less than 
0.05 was considered significant. 
 
RESULTS  
Patients with type 1 diabetes versus 
nondiabetic lean subjects. As compared to 
controls, patients with type 1 diabetes had 
similar MBP, but were characterized 
throughout the test by significantly higher PP, 
HR, PP/MBP, PPxHR and SBPxHR levels 
(Figure 1A, Table 1). When squatting was 
compared with initial standing position, a 
trend for higher increases in PP, PP/MBP and 
PPxHR was observed in patients with type 1 
diabetes than in controls, with a significantly 
higher increase in SBPxHR double product ( 
Table 2). The baroreflex gain calculated 
during the transition from squatting to 
standing was markedly decreased in patients 
with type 1 diabetes compared to controls. 
SqTv and SqTs indices were also significantly 
different in patients with type 1 diabetes 
compared with lean controls (Table 2). There 
was a significant inverse correlation between 
pulsatile stress (PPxHR) and baroreflex gain 
in patients with type 1 diabetes (r = -0.383 ; 
p=0.023), but not in lean controls (r = -0.178; 
NS). 
Patients with type 2 diabetes versus non-
diabetic overweight/obese patients. As 
compared to overweight/obese nondiabetic 
controls, patients with type 2 diabetes had 
similar MBP (hypertension was considered as 
an exclusion criterion in the present study). 
However, they showed higher PP, HR, 
PP/MBP, PPxHR and SBPxHR levels 
throughout the test (Figure 1B, Table 1). 
Increases in PP, PP/MBP, PPxHR and 
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SBPxHR when moving from standing to 
squatting were not significantly different in 
patients with type 2 diabetes and in 
overweight/obese non diabetic controls ( 
Table 2). The baroreflex gain was 
significantly decreased in patients with type 2 
diabetes compared to controls. SqTs index 
(reflecting post-squatting tachycardia), but not 
SqTv index (a marker of bradycardia during 
squatting), was significantly lower in patients 
with type 2 diabetes compared with 
overweight/obese nondiabetic controls (Table 
2). There was a highly significant inverse 
correlation between pulsatile stress and 
baroreflex gain in patients with type 2 
diabetes (r = - 0.719 ; p=0.0001), but not in 
overweight/obese controls (r = - 0.272; NS). 
No significant differences in pulsatile markers 
and CAN indices were noticed between the 
patients with type 2 diabetes treated with 
insulin and those not treated with insulin.  
Patients with type 1 diabetes versus 
patients with type 2 diabetes. On average, 
MBP, PP, HR, PP/MBP, PPxHR and 
SBPxHR levels were comparable in middle-
aged patients with type 1 and type 2 diabetes 
(Figure 1C, Table 1). The transition from 
standing to squatting resulted in similar 
increases in MBP, PP, PP/MBP, PPxHR and 
SBPxHR  in the two groups of diabetic 
patients ( Table 2). Careful analysis of the two 
PP curves showed different kinetics in PP 
increases, with a second phase increase in PP 
in patients with type 1 diabetes that was not 
observed in patients with type 2 diabetes; 
however, the between-group difference during 
the second part of squatting did not reach 
statistical significance (Figure 1C). The 
baroreflex gain was similar in patients with 
type 1 and type 2 diabetes. Accordingly, SqTv 
and SqTs indices were not significantly 
different between the two diabetic groups 
(Table 2). Patients with type 1 diabetes had a 
much longer known disease duration (23 vs 8 
years; p<0.0001), but a much lower 
prevalence of metabolic syndrome (3% vs 
42%; p<0.01) than patients with type 2 
diabetes 
Overweight/obese versus lean subjects 
without diabetes. On average, MBP, PP, HR, 
PP/MBP, PPxHR and SBPxHR levels were 
comparable in obese and lean non diabetic 
individuals of the present study (Table 1). The 
postural change from standing to squatting 
resulted in similar increases in MBP,  PP, 
PP/MBP, PPxHR in overweight/obese and 
lean subjects, with only a trend for higher 
increase in SBPxHR double product (+ 963 ± 
1178 vs + 601 ± 698 mmHg*min-1, p=0.0991) 
in presence of obesity (Table 2). The 
baroreflex gain was significantly lower in 
overweight/obese subjects compared with 
lean individuals (2.97 ± 2.18 vs 4.11 ± 2.26 
mmHg*min-1, p=0.0332), even in absence of 
diabetes. SqTv index was higher in obese 
subjects than in lean controls (p = 0.0011), 
whereas SqTs index was almost similar in the 
two nondiabetic groups (Table 2).  
 
CONCLUSION 
The main findings of the present study 
are: 1) higher PP, PP/MBP, PPxHR and 
SBPxHR levels in middle-aged patients with 
type 1 diabetes compared with lean controls, 
in agreement wit higher pulsatile stress and 
cardiac workload in patients with long-
standing type 1 diabetes ; 2) similarly, higher 
PP, PP/MBP, PPxHR and SBPxHR levels in 
middle-aged non hypertensive patients with 
type 2 diabetes compared with 
overweight/obese nondiabetic controls; 3) the 
absence of significant differences in PP, 
pulsatile index, pulsatile stress, and double 
product between patients with type 1 diabetes 
and with type 2 diabetes matched for age (50 
years on average); and 4) indices of CAN as 
shown by lower baroreflex gain and altered 
SqT indices during squatting  in both patients 
with type 1 diabetes and type 2 diabetes as 
compared to non-diabetic controls. Therefore, 
middle-aged patients with type 1 diabetes or 
with type 2 diabetes are exposed to a 
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comparable pulsatile stress, a known 
cardiovascular and renal risk marker (1-5, 15, 
16). In patients with type 1 diabetes, the 
negative influence of a much longer diabetes 
duration (23 years on average in the present 
study) might be at least partially compensated 
for by the positive influence of lower BMI, 
less insulin resistance and a much lower 
prevalence of metabolic syndrome as 
compared with patients with type 2 diabetes. 
On the contrary, middle-age patients with 
type 2 diabetes are exposed to a high pulsatile 
stress despite a shorter known duration of 
diabetes (8 years on average in our 
population), presumably because the presence 
of other concomitant cardiovascular risk 
factors (even if hypertension was excluded in 
the present study), as shown by a much higher 
prevalence of metabolic syndrome compared 
to patients with type 1 diabetes.   
The observation of higher PP levels in 
patients with type 1 diabetes as compared to 
controls in the age range 40-60 years is in 
agreement with previous studies from our 
group demonstrating an earlier PP increase 
with age in this population (7,8) and with the 
observational data of the large cross-sectional, 
case-control FinnDiane study (3). As PP is 
considered as an indirect marker of arterial 
stiffness, these higher PP results are in 
agreement with accelerated vascular aging in 
the population with type 1 diabetes (6), 
especially patients with chronic poor glucose 
control (18). In the FinnDiane, the ambient 
level of glucose was not associated with 
increased PP, but the time of exposure to 
hyperglycemia appeared to play a 
fundamental role in the process of premature 
arterial stiffening in patients with type 1 
diabetes (3). In the EURODIAB Prospective 
Complications Study, PP was significantly 
associated with all-cause mortality and a 
mean 12 mm Hg higher PP was observed in 
patients with type 1 diabetes who died as 
compared to that of those who survived (5).  
Decreased baroreflex gain was 
observed in our patients with type 1 diabetes, 
reflecting the presence of CAN after > 20 
years of diabetes (19). This was confirmed by 
altered SqTs and SqTv indices during the 
squatting test, markers of parasympathetic and 
sympathetic dysfunction, respectively (10). 
CAN exposes diabetic patients to an increased 
mortality risk (19). There may be some 
connection between PP and CAN (8), 
between aortic stiffness and CAN (20) and 
between arterial stiffness, cardiovagal 
baroreflex sensitivity and postural blood 
pressure changes (21). Increased SBP was 
identified as a factor associated with an 
increased risk of developing CAN in the 
cohort of patients with type 1 diabetes of the 
EURODIAB Prospective Complications study 
(22). The pathophysiological mechanism 
linking CAN to arterial stiffness in patients 
with type 1 diabetes remains unknown, but 
this association persisted after adjustment for 
potential confounders such as baseline 
HbA1c, HDL cholesterol, and smoking  
history (23). In the present study, we found a 
significant relationship between pulsatile 
stress and baroreflex gain as a marker of CAN 
in patients with type 1 diabetes. In patients 
with type 2 diabetes, markers of CAN are also 
present (11), although less marked than in 
patients with prolonged type 1 diabetes (7). 
The relationship between PP and CAN is less 
well known in patients with type 2 diabetes 
even if associations between autonomic 
neuropathy, vascular dysfunction and 
hyperinsulinemia have been demonstrated 
(24). Interestingly, a remarkable significant 
inverse correlation was noticed between 
pulsatile stress and baroreflex gain in the 
group of patients with type 2 diabetes of our 
study.  Several mechanisms may underlie the 
association between arterial stiffness and 
impaired cardiovagal baroreflex sensitivity. 
The stiffness of the carotid arteries and the 
aorta, where the arterial baroreceptors are 
located, may affect the stretch-sensitive 
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receptors and hence baroreflex sensitivity. In 
addition to structural vascular changes, 
functional mechanisms associated to 
endothelial dysfunction may also contribute to 
the impairment of baroreflex sensitivity 
associated with arterial stiffness (21).  
Patients with type 2 diabetes also 
showed increased PP, pulsatility index and 
pulsatile stress as compared to 
overweight/obese non diabetic individuals 
matched for BMI, age and gender. This was 
observed despite the absence of hypertension 
and a much shorter duration of diabetes when 
compared to the population with type 1 
diabetes analyzed in the present study. It is 
well known, however, that type 2 diabetes 
remains silent during an average of 10 years 
before diagnosis and initiation of treatment in 
most cases. Thus, selected patients may have 
a longer duration of type 2 diabetes than the 
average 8-year known duration noticed in the 
present population. In order to avoid the 
potential bias of hypertension and the 
interferences of antihypertensive agents, we 
deliberately selected type 2 diabetes patients 
without hypertension. Despite normal MBP, 
middle-aged patients with type 2 diabetes had 
higher PP and pulsatile stress and higher 
SBPxHR double product, two CVD risk 
markers (16). Increased PP levels have been 
repeatedly demonstrated in large longitudinal 
studies in patients with type 2 diabetes 
mellitus and shown to be associated with a 
higher incidence of cardiovascular events 
(1,2). 
Some limitations of the present study 
should be discussed. Several studies have 
demonstrated that absolute brachial and finger 
PP measurements are not identical with larger 
differences in SBP. However, the differences 
were generally small and not considered of 
clinical relevance (13). Furthermore, some 
studies have shown a good concordance 
between periphery (finger, as in the present 
study) and central (aortic, now recognized as 
the most important risk factor) BP 
measurements (25). Nevertheless, PP 
measured at the finger site may not 
necessarily reflect central PP because of the 
amplification phenomenon. Second, glucose 
control of patients with type 1 diabetes 
evaluated in the present study was far from 
optimal, despite intensified insulin therapy. 
Therefore, our results could not be necessarily 
extrapolated to patients with near 
normoglycemia for many years as chronic 
hyperglycemia seems to play a major role in 
accelerating arterial stiffness (18). Third, 
patients with type 2 diabetes selected in the 
present study did not have hypertension. 
Therefore, the similar results in markers of 
pulsatile stress in middle-aged patients with 
type 1 and type 2 diabetes should be 
interpreted in this context. We cannot exclude 
that overweight/obese patients with type 2 
diabetes and hypertension may be exposed to 
a higher vascular stress than lean 
normotensive patients with type 1 diabetes at 
the same age. This would be certainly the case 
for the SBPxHR double product, but might 
also be true for the various pulsatility 
markers. Fourth, very few patients had 
positive microalbuminuria in the two diabetic 
cohorts analyzed in the present study, because 
we excluded patients with hypertension or 
antihypertensive agents. Therefore, we were 
not in a position to study the possible 
relationship between pulsatile stress and early 
renal alterations as shown in previous studies 
(15).  
 In conclusion, middle-aged patients 
with a long duration of type 1 diabetes have 
similarly increased pulsatile stress as 
compared to age-matched patients with type 2 
diabetes characterized by a shorter duration of 
the disease but the presence of other vascular 
risk factor such as obesity and insulin 
resistance, but no hypertension. In addition, 
both diabetic groups have markers of CAN 
with a reduced baroreflex gain as compared to 
non diabetic controls. The combination of 
these risk factors may contribute to increase 
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the CVD risk in type 1 diabetic patients with a 
long exposition to chronic hyperglycemia in a 
similar fashion as patients with type 2 
diabetes whose high CVD risk is well known.   
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Table 1: Characteristics of middle-aged diabetic patients with type 1 diabetes (T1DM), patients 
with type 2 diabetes (T2DM), non-diabetic lean controls (LC) and non-diabetic overweight/obese 
controls (OC) (20 men and 20 women in each group), and average values of mean blood pressure 
(BP), systolic BP, diastolic BP, pulse pressure (PP), pulsatility index (PP/mean BP), heart rate 
(HR), pulsatile stress (PPxHR), systolic BP x HR double product (SBPxHR) recorded during the 
whole 3-min squatting test. Results are expressed as mean ± SD. NA : not applicable. NS : non 
significant. BMI : body mass index 
 
     P value 
 T1DM LC T2DM OC T1DM vs LC 
T2DM 
vs OC 
N (Male/Female) 20/20 20/20 20/20 20/20       
Age (yrs) 50 ± 6 50 ± 6 50 ± 6 50 ± 6 0.8888    0.8971  
Diabetes duration (yrs) 23 ± 11 - 8 ± 7  - NA NA 
BMI (kg/m2) 23.0 ± 2.0 22.2 ± 1.6 29.7 ± 3.7  28.6 ± 2.7   0.0642   0.1288  
HbA1c (%) 8.4 ± 1.3 - 7.8 ± 1.6 - NA NA 
Mean BP (mm Hg) 84 ± 13  85 ± 12 88 ± 13 86 ± 12 0.9719    0.5991  
Systolic BP (mm Hg) 126 ± 21  120 ± 21 128 ± 20 122 ± 18 0.1649   0.1087  
Diastolic BP (mm Hg) 66 ± 11  68 ± 10 70 ± 13 70 ± 10  0.6195  0.1662  
PP (mm Hg) 59 ± 13 52 ± 15 58 ± 16 52± 13 0.0160 0.0451 
PP/Mean BP 0.703 ± 0.121 0.610± 0.139 0.677 ± 0.245 0.603 ± 0.152 0.0020 0.1082  
HR (bpm) 88 ±13 80 ± 9 91 ± 10 84 ± 13 0.0029 0.0029 
PP x HR product (mm 
Hg*min-1) 5263 ± 1563 4121 ± 1120 5359 ± 1641 4321 ± 1277 0.0004 0.0023 
SBP x HR product 
(mm Hg*min-1) 11120 ± 2947 9593 ± 1771 12082 ± 2521 10195 ± 2291 0.0039 0.0008 
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Table 2: Changes (delta) in mean blood pressure (BP), systolic BP, diastolic BP, pulse pressure 
(PP), pulsatility index (PP/mean BP), heart rate (HR), pulsatile stress (PPxHR), systolic BP x HR 
double product (SBPxHR) occurring during the transition from the initial standing position to the 
squatting position in middle-aged diabetic patients with type 1 diabetes (T1DM), patients with 
type 2 diabetes (T2DM), non-diabetic lean controls (LC) and non-diabetic overweight/obese 
controls (OC) (20 men and 20 women in each group). Mean values of baroreflex gain as well as 
SqTv and SqTs indices of cardiac autonomic neuropathy are also presented in the four groups.  
Results are expressed as mean ± SD. NS : non significant. NA : not applicable. 
 
     P value 
 T1DM LC T2DM OC T1DM vs LC 
T2DM 
vs OC 
N 40 40 40 40       
Delta mean BP 
(mm Hg) 8 ± 7 5 ±4 10 ±9 7 ±8 0.0185  0.0875  
Delta systolic BP (mm 
Hg) 13 ± 11 8 ± 7 14 ± 14  9 ± 11 0.0101 0.0754  
Delta diastolic BP (mm 
Hg) 3 ± 5 1 ± 4 6 ±7
  3  ± 7  0.0141  0.1391  
Delta PP (mmHg) 10 ± 8 7 ± 6 8 ± 11  6 ± 7 0.0705 0.1662  
Delta PP/Mean BP 0.127 ± 0.110 0.087 ± 0.074 0.095 ± 0.133 0.065 ± 0.082 0.0593 0.2371  
Delta HR (/min) -6  ± 7  -6 ± 6 -6 ± 7 -2 ± 7 0.7449  0.0123 
Delta PPxHR product  
(mmHg*min-1) 557 ± 935 276 ± 532 449 ± 942 404 ± 743 0.1029   0.8132  
Delta SBPxHR product 
(mmHg*min-1) 1136 ± 1270  601 ± 698 1236 ± 1440 963 ± 1178 0.0227 0.3611  
Baroreflex gain 
(mmHg*min-1) 2.20 ± 1.73 4.11 ± 2.26 2.05 ± 1.31 2.97 ± 2.18  0.0002 0.0351 
SqTv index 0.88 ±0.08  0.81 ± 0.13 0.90 ± 0.07 0.89 ± 0.09  0.0059 0.7553  





Figure 1: Changes in mean arterial blood pressure (MBP), pulse pressure (PP) and  heart rate 
(HR) during a posture test [1 min standing  – 1 min squatting (grey zone) – 1 min standing]. (A) :  
40 patients with type 1 diabetes (open circles) versus 40 non-diabetic (full circles) subjects 
matched for age, sex and BMI; (B):  40 patients with type 2 diabetes (open triangles) versus 40 
non-diabetic (full triangles) subjects matched for age, sex and BMI; and (C) 40 patients with type 
1 diabetes (open circles) versus 40 patients with type 2 diabetes (open triangles) subjects 
matched for age and sex. 
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